Abstract | BACKGROUND: METHODS: A global economic model was adapted to the UK National Health Service (NHS), with primary outcomes of direct healthcare costs and quality-adjusted life years (QALYs). Efficacy, measured as relative risk reduction of skeletal-related events (SREs), was obtained from clinical trials. Resource use data for i.v. bisphosphonates and the cost of managing SREs were obtained from published studies. Hospital management and SRE treatment costs were taken from unit cost databases. Monthly drug acquisition costs were obtained from the British National Formulary. Utility scores were applied to time with/without an SRE to adjust survival for quality of life. Model design and inputs were validated through expert UK clinician review. RESULTS: CONCLUSIONS:
|
Authors | E De Cock, J Hutton, P Canney, J J Body, P Barrett-Lee, M P Neary, G Lewis |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 13
Issue 12
Pg. 975-86
(Dec 2005)
ISSN: 0941-4355 [Print] Germany |
PMID | 15871033
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Diphosphonates
- Imidazoles
- Zoledronic Acid
- Pamidronate
- Ibandronic Acid
|
Topics |
- Administration, Oral
- Bone Neoplasms
(drug therapy, secondary)
- Breast Neoplasms
(drug therapy)
- Clinical Trials, Phase III as Topic
- Cohort Studies
- Cost-Benefit Analysis
- Diphosphonates
(administration & dosage, economics)
- Female
- Humans
- Ibandronic Acid
- Imidazoles
(administration & dosage, economics)
- Infusions, Intravenous
- Neoplasm Metastasis
- Pamidronate
- Quality of Life
- State Medicine
- United Kingdom
- Zoledronic Acid
|